BAB VI KESIMPULAN DAN SARAN
6.2 Saran
1. Diperlukan modifikasi life styledengan pengaturan diet rendah garam dan purin yang tepat pada populasi hipertensi essensial dan normotensi suku aceh asli di kabupaten Aceh Utara.
2. Diperlukanpenelitianepidemiologi prospektif
lanjutandenganjumlahsampel yang lebihbesar, waktu penelitian yang lebih lamadanmulticenter terhadap suku aceh asli di kabupaten lainnya di propinsi NAD.
3. Prioritas pemilihan obat anti hipertensi golongan ARB Losartan yang bersifat urikosurik pada penderita hipertensi essensial suku Aceh asli di kabupaten Aceh Utara.
4. Diperlukan penelitian prospektif lanjutan yang bersifat eksperimental apakah pengobatan hiperurisemia diperlukan pada penderita hipertensi essensial.
DAFTAR PUSTAKA
Agamah ES, Srinivasan SR, Webber LS, Berenson GS (1991): Serum uric acid and its relations to cardiovascular disease risk factors in children and young adults from a biracial community: The Bogalusa Heart Study. J Lab Clin Med, 118:241-249.
Alderman MH, Cohen H, et al (1999). Serum Uric Acid and Cardiovascular Events in Successfully Treated Hypertensive Patients. Hypertension, 34:144-150
Alderman, MH (2007). Uric Acid and Cardiovascular Disease. Circulation: 880-83.
Aminullah A, Rukman Y, Munasir Z, Sastroasmoro S (2007). Variabel dan Hubungan antar Variabel. In: Sastroasmoro S dan Ismael S (ed). Dasar –Dasar Metodologi Penelitian Klinis Edisi Ketiga. Jakarta: Sagung Seto , 255-78. Bakri S, Lawrences (2008). Genetika Hipertensi, dalam Hipertensi dan Ginjal, 19-31.
Becker & Meenaskshi J. Clinical gout and pathogenesis of hyperuricaemia (2005). In Arthritis and Allied Conditions. A Textbook of Rheumatology Ed-13. Baltimore. Williams & Wilkins a Wavelry comp, 2303-2339.
Beevers G,Lip GY,et al (2001). ABC of hypertension (The pathophysiology of hypertension). BMJ, 322 : 912-916.
Berry CE and JM Hare (2004). Xanthine Oxidoreductase and Cardiovascular Disease: Molecular Mechanism and Pathophysiological Implications. Am J Physiol : 589-606.
Blumenfeld JD and Laragh JH (2008). Hypertension and the kidney from Brenner and Rector’s. The Kidney Ed-8, 1465-1516.
Bradlow A (1998). Symptomless hyperuricaemia in patients with essential hypertension and normal renal function. Journal of Human Hypertension, 12: 147-148.
Bulpitt CJ (1975). Serum Uric Acidin hypertensive patients” British Heart Journal, 37: 1210-1215.
Brown MJ, Palmer CR, Casteigne A. Morbidity and mortality in patients randomized to double blind treatment with a long acting calcium channel blocker or diuretic in the International Nifedipine GITS Study : Intervention as a Goal in Hypertension Treatment (INSIGHT) (2000). Lancet ;536: 366-372.
Campo C, Ruilope LM, Segura J (2001). Serum urate as a marker of hypertension severity. J Hypertension, in press.
Canon PJ, Stason WB, Demartini FE, Laragh JH, Sommers SC (1966). Hyperuricemia in primary and renal hypertension. New England Journal of Medicine ; 275:457-464.
Cohen MG, Emmerson BT (1994). Gout in Rheumatology, JH Klippel, PA Dippe (eds), Part 2. St Louis Baltimore. Mosby : 12.1-12.16.
Conen D, Wietlisbach V, et al (2004). Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health, 4:1-9.
Cooper RS, Tayo B (2008). Hypertension Primer: The Essentials of High Blood Pressure : Basic Science, Population Science, Clinical Management by Izzo JL, Sica DA, Black HR (eds) Ed-4. Lippincott Williams & Wilkins, B (74): 240-242.
Culleton BF, Larson MG, Kannel WB, Levy D (2006).Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med, 131:7-13.
Emmerson, BT (1983). Hyperuricaemia and Gout in Clinical Practice. ADIS Health SciencePress, Sidney.
Feig DI, Kang DH, Johnson RJ (2008). Uric Acid and Cardiovascular Risk. N Eng J Med: 1811-21.
Feig DI. Uric Acid and Hypertension (2011). Semin Nephrol, 31: 441-446. Fessel WJ (1979). Renal outcomes of gout and hyperuricemia. American journal of medicine, 67: 74 - 82.
Ghazali MV, Sastromihardjo S, Rochani S, Soelaryo T, Pramulyo H. Studi Cross-Sectional (2007). In: Sastroasmoro S dan Ismael S (ed). Dasar –Dasar Metodologi Penelitian Klinis Edisi Ketiga. Jakarta: Sagung Seto : 112-26.
Goldstein HS, Manowitz P (1993). Relation between serum uric acid and blood pressure in adolescents. Annals of Hum Biology, 20(5): 423- 431.
Hayden MR, Tyagi SC (2004). Uric Acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutrition & Metabolism, I ;10: 1-15.
Hediger MA, Johnson RJ, Miyazaki H, EndouH (2005). Molecular Physiology of Urate Transport. Am J Physiol :125-33.
Heinig M and RJ Johnson (2006). Role of Uric Acid in Hypertension, Renal Disease, and Metabolic Syndrome. Cleveland Clinic Journal of Medicine :1059-64.
Iseki K, Oshiro S, et al (2001). Significance of Hyperuricemia on the Early Detection of Renal Failure in a Cohort of Screened Subjects. Hypertension Res, 24:691-697.
Johnson RJ, Kang DH, Feig D, Kivlighn S, Kannelis J, Watanabe S, Tuttle KR (2003). Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension, 41:1183-1190.
Johnson RJ, Segal MS,Srinivas T, et al (2005) . Essensial Hypertension, Progressive Renal Disease, and Uric Acid: A Pathogenic Link? J Am Soc Nephrol, 16:1909-1919.
Kaplan NM (2002). Primary Hypertension: pathogenesis. Kaplan’s clinical hypertension. Ed-8 Philadelphia. Lippincott Williams & Willkins, 56-135. Kelly WN, Wortmann RL (1997). Crystal-associated synovitis: gout and hyperuricemia. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, editors. Textbook of rheumatology. Ed-5 Philadelphia. WB Saunders, 1313-47.
Kinsey D, Walther R, Wise HS, Smithwick R (1961). Incidence of hyperuricemia in 400 hypertensive patients” Circulation, 24:972.
Kolbel F, Gregorova I, Souka J. Serum uric acid in hypertensives (1965). Lancet, 1; 519.
Kuang-HY, Yeong-JJW (2006). Gout and Hyperuricemia : Recent Advances and a Systematic Review. J Rheumatol R.O.C, 20: 6-18.
Kumar A, Singh YN, Malaviya AN, Chaudhary K, Tripathy S (1990). Clinical profile, therapeutic approach and outcome of gouty arthritis in northern India. Journal of Association of Physicians of India, June, 38(6): 400-402. Lawrence GS (2010). Implikasi Klinis Disfungsi Endotel dan Radikal Bebas. Makassar: FK UNHAS.
Lehto S, Niskanen L, Ronnemma T, Laakso M (1998). Serum Uric Acid is A Strong Predictor of Stroke in Patients with Non-Insulin Dependent Diabetes Mellitus. Stroke : 635-39.
Lippi G, Targher G, et al (2008). High Serum Uric Acid and a Novel Risk Factor for Type 2 Diabetes. Diabetes Care, 31(9) : e 68.
Madiyono B, Moeslichan S, Sastroasmoro S, Budiman I, Purwanto SH (2007). Perkiraan Besar Sampel. In: Sastroasmoro S dan Ismael S (ed). Dasar –Dasar Metodologi Penelitian Klinis Edisi Ketiga. Jakarta: Sagung Seto, 302-30. Mazzali M, Kanbay M, Segal MS, Shafiu M, Jalal D, et al (2010). Uric Acid and Hypertension : Cause or Effect? Current Rheumatol, 12:108-117.
Mei Z, Ying F. An Analysis on the relationship between essensial hypertension and hyperuricemia (2002). China Academic Journal Publishing House, 27 (3):223-226.
Melander O (2001). Genetic Factors in Hypertension- What is known and What Does It Mean? Blood Pressure, 10 : 254-270.
Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG (1980). Serum Uric Acid in Essential Hypertension: an indicator of renal vascular involvement. Annals of Internal Medicine, 93:817-821
Mladinescu OF, Savoiu G, Serban C, Noveanu L, Gaita D, Muntean D (2008). The Rule of Hyperurisemia in Endothelial Dysfunction Induced by Hypertension. Romanian J. Biophys : 329-36.
Nakagawa T,Kang DH (2006). Unearthing uric acid: An ancient factor with recently found significance in renal and cardiovascular disease. Kidney International, 69: 1722-1725.
Neil J. Evaluation of serum uric acid in essential hypertension (2005). Dissertation submitted to Rajiv Ghandi University of Health Science, Karnataka Bangalore.
Niskanen L, Laaksonen DE (2006). Serum Uric Acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance, The Finnish Diabetes Prevention Study. Diabetes Care, 29: 709-711.
Niskanen LK, Laaksonen DE, Nyysonen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT (2004). Uric Acid Level as a Risk Factor for Cardiovascular and All Cause Mortality in Middle Aged Men: A Prospective Cohort Study. Arch Itern Med, :1541-46.
Obermayr RP, Temml C, et al (2008). Elevated Uric Acid Increases the Risk for Kidney Disease. Clinical Epidemiology. J Am Soc Nephrol :1-7.
Oparil S, Zaman MA, et al (2003). Pathogenesis of hypertension. Ann Intern Med, 139:761-776.
Purwanto, Bambang (2009). Pathogenesis, Etiology, and Management of Hypertension and Nefrotoxic Agents. Disampaikan pada Half Day Simposium: Renal Disease Induced by Nefrotoxic Agents. Surakarta.
Putra, Tjokorda Raka (2006). Hiperurisemia. In: Sudoyo dkk (ed). Buku Ajar Ilmu Peyakit Dalam Jilid II Edisi IV. Jakarta: FKUI : 1213-17.
Riskerdas R (2007). Prevalensi Penyakit Kronis ( Persendian, Hipertensi, Stroke pada Penduduk) dalam 1 tahun terakhir Menurut Karakteristik Responden di NAD: 79-80.
Ruilope LM and Rodicio JL (2001). The Kidney in Arterial Hypertension. Nephrol Dial Transplant, 16 (Suppl 1): 50-52.
Ruilope LM, Lahera V, Rodicio JL, Romero JC (1994). Are renal hemodynamics a key factor in the development and maintanance of arterial hypertension in humans? Hypertension 1994;23:3-9.
Ruilope LM (2001). Kidney function, a sensitive predictor of cardiovascular risk. Am J Hypertension, in press.
Savoiu G, Serban C, et al (2008). The Role of Hyperuricemia in Endothelial Dysfunction Induced by Hypertension. Romanian J. Biophys, 18 (4): 329-336. Schumacer Jr HR. Hyperuricaemia and Gout (1992). In Rheumatology APLAR, 243-293.
Sidabutar RP (1990). Hipertensi Esensial. Ilmu Penyakit Dalam jilid II, Balai Penerbit FK UI Jakarta : 205-212.
The Seventh Report on the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (2004). NIH Publication No. 04-5230, August
Tykarski A. Evaluation of renal handling of uric acid in essential hypertension; hyperuricemia related to decreased urate secretion. Nephrology 1991, 59(3) : 364-368.
Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Brunetti P (2000). Relation between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension. The PIUMA Study Hypertension : 1072-78.
Viazzi F, Leoncini G, et al (2007). Mild Hyperuricemia and Subclinical Renal Damage in Untreated Primary Hypertension. American Journal of Hypertension, 20: 1276-1282.
Waring WS, Esmail S (2005). How Should Serum Uric Acid Concentration be Interpreted in Patients with Hypertension. Current Hypertension Reviews : 89-95.
Waring WS, Webb D, Maxwell SRJ (2000). Uric acid as a risk factor for cardiovascular disease. Q J Med, 93: 707-713.
Wisesa IBN, Suastika K (2009). Hubungan antara konsentrasi Asam Urat Serum dengan Resistensi Insulin Pada Penduduk Suku Bali Asli Di Dusun Tenganan Pengringsingan Karangasem. J.Peny. Dalam, vol. 10 (2) Mei : 110-122
Yeon HK, Yeong DS, Sung PS (1986). Observation of the serum uric acid in essential hypertension. The Korean Journal of Internal Medicine, 1(1) : 14-20. Yogiantoro, Mohammad (2006). Hipertensi Esensial. In: Sudoyo dkk (ed). Buku Ajar Ilmu Peyakit Dalam Jilid I Edisi IV Jakarta FKUI : 610-14
Yongkuan W, Meijing L, Jue L (2008). Elevated serum uric acid level as predictor for cardiovascular and all cause mortality in Chinese patients with high cardiovascular risk. Journal of Geriatric Cardiology, 5:15-20.
Zoccali C, Maio R 2006). Uric Acid and Endothelial Dysfunction in Essential Hypertension. J Am Soc Nephrol, 17: 1466-1471.
LAMPIRAN 1
LAMPIRAN 2
LEMBAR PENJELASAN KEPADA CALON SUBJEK PENELITIAN
Selamatpagi / siangBapak / Ibu, pada hariini, saya, dr.Abida, akanmelakukanpenelitian yang berjudul “ PROPORSI HIPERURISEMIA
PADAPOPULASI HIPERTENSI ESSENSIAL SUKU ACEH DI
KABUPATEN ACEH UTARA”.Penelitianinibertujuanuntukmengetahuiproporsihiperurisemia pada
populasihipertensiessensial dan normotensisuku Aceh di kabupaten Aceh Utara.
Bapak /ibu yang bersediamengikutipenelitianininantinyaakandiharuskanmengisisuratpersetujuanik
utdalampenelitian, mengikutiwawancara, pemeriksaanlaboratoriumberupapemeriksaandarahsebanyak 10 cc
olehahlinyauntukmenilaidarahrutin dan fungsi. Setelahituakandibedakanmenjadiduakelompok, yaitukelompoknormotensi dan
hipertensi .
Selanjutnyakepadakeduakelompokdilakukanpemeriksaandarahuntukmeng
etahuikadarasamuratserum dan hasil yang didapatkandarikeduakelompokkemudiandiambil rata-ratanya dan dibandingkan.
Biayapenelitianmenjaditanggungjawabpeneliti. Bilamasihterdapatpertanyaan, makaBapak / Ibudapatmenghubungisaya :
Nama : dr. Abida
Alamat : Jl. Gajah No. 39 Medan 20211 No Telp : 081370541374 ( Hp )
Peneliti
LAMPIRAN 3
SURAT PERSETUJUAN SETELAH PENJELASAN ( INFORMED CONSENT )
Saya yang bertanda tangan di bawah ini :
Nama : ...
Alamat : ... Umur : ... Jenis Kelamin : Laki – laki / perempuan
Setelah mendapat penjelasan dari peneliti tentang kebaikan dan keburukan prosedur penelitian ini dan saya telah memahaminya, menyatakan bersedia untuk ikut dalam penelitian tentang Proporsi Hiperurisemia pada Populasi Hipertensi Essensial Suku Aceh di Kabupaten Aceh Utara.
Demikianlah surat pernyataan bersedia ikut dalam penelitian ini saya buat untuk dapat dipergunakan seperlunya.
Lhokseumawe, ...2010
Saksi
LAMPIRAN 4
KERTAS KERJA PROFIL PESERTA PENELITIAN
ANAMNESIS PRIBADI Nama : Usia : JenisKelamin : Alamat : No telp/Hp : Suku : Status Marital : BB kg TB cm IMTkg/m Diagnosis Hipertensisejak : 2
Riwayatpenggunaanobat anti hipertensi :
SilsilahKeturunan III. RiwayatPenggunaanObat : o Kortikosteroid o Siklosporin o Pirazinamid o Ethambutol
o Aspirin dosis < 2gr/hari o HCT o Furosemid aceh Buyut Kakek aceh Ayah aceh Subjekpenel itian i
IV. Riwayat Penyakit :
o Hipertensi sekunder karena obat obatan o Keganasan
o Gangguan ginjal (Kadar Creatinin serum >1 .4 mg/dl) o Gagal jantung
o Penyakit Jantung Koroner o Diabetes Melitus
o Pre Eklamsia
o Penyakit Pembuluh Darah Perifer o Alkoholik
o Penyakit Ginjal Kronis (Cr Cl < 60 ml/mnt)
o Hipertrigliseridemia (trigliserida darah > 150 mg/dl)
V. Laboratorium dan Pemeriksaan Penunjang
Urin rutin : Protein urin ( )
RFT : Ureum mg/dl Creatinin mg/dl Uric acid mg/dl
Cr Cl : ml/mnt
EKG :
Foto Toraks :
VI. PEMERIKSAAN TEKANAN DARAH :
Rata-rata kunjungan I mm Hg Rata-rata kunjungan II mm Hg Rata-rata kunjungan III mm Hg
LAMPIRAN 5
DAFTAR RIWAYAT HIDUP
I. DATA PRIBADI
Nama : Dr. Abida
Tempat/Tgl Lahir : Medan / 07 September 1976 Suku/Bangsa : Indonesia
Agama : Islam
Alamat : JL Gajah no. 39 A Medan
No. Handphone : 081370541374
II. RIWAYAT PENDIDIKAN
PENDIDIKAN LAMA PENDIDIKAN TEMPAT
SD SMP SMA Fakultas Kedokteran Program SpesialisPenyakitDa lam 1982-1988 1988-1991 1991-1994 1994-2000 2007-Sekarang SDN 060805 Medan SMP Josua 1 Medan SMUN 8 Medan FK-USU FK-USU
III. KEANGGOTAAN PROFESI
1. IkatanDokter Indonesia (IDI)
2. PersatuanAhliPenyakitDalam Indonesia (PAPDI)
IV. KARYA ILMIAH DI DEPARTEMEN ILMU PENYAKIT
DALAM
1. Abida, Tunggul Sukendar, Harun Rasyid Lubis. Nefritis Lupus Kelas IV. Konas X PERNEFRI & Annual Meeting, Bandung 28-30 November 2008.
2. Abida, Tambar Kembaren, Armon Rahimi, Josia Ginting. Penyakit Weil. KOPAPDI XIV, Jakarta 11-14 November 2009.
1. PesertaSimposium Road Show 2008 Eli Lilly “Insulin Training for Excellence” PengurusBesarPerhimpunanDokterSpesialisPenyakitDalam Indonesia (PBPAPDI) &PengurusBesarPerkumpulanEndokrinologi Indonesia (PBPERKENI). Medan, 26 Januari 2008.
2. PesertaSimposium “How to Choose an Appropriate OAD”
PertemuanIlmiahTahunan (PIT) IX 2008 DepartemenPenyakitDalamFakultasKedokteranUniversitas Sumatera Utara. Medan, 15 April 2008.
3. PesertaSimposium “Critical Care and Emergency Medicine”. Medan, 09-10 Mei 2008.
4. PesertaSimposium “Management Hypertension and Chronic Heart Failure”. Medan, 24 Januari 2009.
5. PesertaSimposium “Finding the Missing Link in Energy Metabolism”. Medan, 17 Maret 2009.
6. Peserta Workshop “Achieving Ambitious Glycaemic Target in Diabetes : Stepwise Intensification of Insulin Treatment from Basal to Basal Plus/Bolus”. Medan 12 Juli 2009.
7. PesertaSimposium “Scientific Meeting Attaining Greater BP Reduction and Organ Protection”. Medan, 01 Agustus 2009.
8. Peserta Workshop on Osteoporosis “Osteoporosis Crunch Time”. Medan, 08 Agustus 2009.
9. PesertaSimposiumGastroentero-Hepatologi Update VII 2009. Medan, 09-10 Oktober 2009.
10.Peserta Kursus USG Tahap I. Dept IPD FK-USU – Institut Kedokteran Ultrasonografi Indonesia. Medan, 2009.
11.PesertaSimposium “Early Insulin Inisiation, How, When and What Insulin According to Daily Practice Need. Medan, 21 November 2009.
12.Peserta 14th
13.Peserta Roadshow Ilmiah PBPAPDI “PenggunaanTestosteronpada Aging Male”. Medan, 06 Maret 2010.
National Congress of the Indonesian Society of Internal Medicine (KOPAPDI XIV). Jakarta, 11-14 November 2009.
14.PesertaSimposium“Advanced Strategies in Optimizing Diabetes Management. Bali, 12 Juni 2010.
15.Peserta Seminar “Carb Smart Nutrition Update for Diabetic Complication Prevention”. Medan, 12 Juni 2010.
16.PanitiaSimposium “Clinical rheumatology in Daily Practice”. Medan, 31 Juli-01Agustus 2010.
17.PesertaSimposium “Hepatitis Update”. Medan, 23 Februari 2011.
18.Peserta Roadshow “Medical Skill Upgrade” (MEDSKUP) Workshop Cardio-Metabolic. Medan, 02 April 2011.
19.Peserta PIT XII 2011 PenyakitDalamPertemuanIlmiahNasional PERPARI. Medan 28-30 April 2011.
20.Peserta Workshop “Management Acute Coronary Syndrome”. Medan, 23-25 Juni 2011.
21.Panitia Workshop “Penyuntikan Intra Artikular”. Medan, 07 Juli 2011. 22.Peserta Workshop “ NyeriCampuran”. Medan, 07 Juli 2011.
23.Peserta Workshop “TehnikPemeriksaanFisikpadaBerbagaiJenisPenyakit”. Medan, 08 Juli 2011.
24.Panitia Workshop “PendidikanPelatihan USG Muskuloskeletal”. Medan, 08 Juli 2011.
25.PesertaSimposium “Clinical rheumatology in Daily Practice”. Medan, 09 Juli 2011.
26.PesertaSimposium“ Lymphoma Update :
DeteksiDinidanPenatalaksanaan”. Medan, 16 Juli 2011.
27.PesertaSimposium“ Pathogenesis, Prevention and Management Diabetic Vascular Complications”. Minggu, 20 November 2011.
28.Peserta Workshop Infection Update IV “Current Challenges Management on Infection”. Medan, 25 November 2011.
29.Peserta Simposium “8th
30.Panitia 15
Jakarta Endocrine Meeting. Jakarta, 16-17 Juni 2012.
th
National Congress of the Indonesian Society of Internal Medicine (KOPAPDI XV). Medan , 12-15Desember 2012
LAMPIRAN 6
ANALISIS STATISTIK
Non Parametrik Test (HT)
Non Parametrik test (Normal)
T Test (Hipertensi)
One-Sample Kolmogorov-Smirnov Test
69 52,23 10,218 ,095 ,095 -,076 ,792 ,556 69 5,377 2,6015 ,166 ,166 -,083 1,381 ,044 69 156,16 19,500 ,159 ,159 -,088 1,318 ,062 69 91,01 10,866 ,233 ,233 -,173 1,934 ,001 69 39,29 4,141 ,122 ,122 -,088 1,014 ,255 69 7,299 ,8235 ,074 ,074 -,061 ,616 ,842 69 134,22 20,244 ,102 ,102 -,091 ,848 ,468 69 120,51 15,417 ,110 ,110 -,050 ,914 ,374 69 197,48 21,043 ,158 ,096 -,158 1,315 ,063 69 32,28 8,883 ,083 ,065 -,083 ,691 ,726 69 ,868 ,2452 ,088 ,073 -,088 ,731 ,660 69 14,41 3,735 ,119 ,094 -,119 ,986 ,286 69 100,97 18,823 ,115 ,115 -,084 ,953 ,323 69 58,77 7,205 ,151 ,062 -,151 1,250 ,088 69 165,70 7,423 ,105 ,083 -,105 ,875 ,429 69 21,302 1,0405 ,120 ,063 -,120 ,995 ,276 69 80,676 19,6687 ,138 ,138 -,122 1,143 ,146 Usia (tahun) Lama HT TDS TDD HDL AU TG LDL T CHOL Ureum Creatinin BUN KGD Berat badan Tinggi badan IMT Cr Cl N Mean Std. Deviation Normal Parametersa,b
Absolute Positive Negative Most Extreme Differences
Kolmogorov-Smirnov Z Asymp. Sig. (2-tailed)
Test distribution is Normal. a.
Calculated from data. b.
One-S ample Kolm ogorov-Sm irnov Test
68 49,16 9,093 ,162 ,162 -,083 1,334 ,057 68 119,41 9,601 ,201 ,196 -,201 1,657 ,008 68 77,72 5,425 ,369 ,278 -,369 3,040 ,000 68 57,57 11,949 ,101 ,096 -,101 ,832 ,492 68 5,210 1,1496 ,085 ,073 -,085 ,699 ,713 68 116,25 27,089 ,113 ,049 -,113 ,928 ,356 68 106,76 12,785 ,113 ,113 -,068 ,935 ,346 68 180,84 27,994 ,137 ,089 -,137 1,127 ,158 68 20,82 5,987 ,113 ,113 -,098 ,934 ,347 68 ,734 ,1850 ,148 ,148 -,088 1,218 ,103 68 10,29 3,115 ,185 ,185 -,130 1,523 ,019 68 102,91 18,688 ,121 ,121 -,068 ,996 ,275 68 58,82 6,990 ,128 ,060 -,128 1,053 ,217 68 165,29 7,709 ,126 ,092 -,126 1,041 ,228 68 21,442 1,0783 ,113 ,080 -,113 ,935 ,347 68 99,090 21,4183 ,088 ,071 -,088 ,727 ,665 Us ia (t ahun) TDS TDD HDL AU TG LDL T CHOL Ureum Creatinin BUN KGD Berat badan Tinggi badan IMT Cr Cl
N Mean St d. Deviat ion Normal Parametersa,b
Absolute Positive Negative Most Extreme Differenc es
Kolmogorov-Smirnov Z As ymp. Sig. (2-tailed)
Test distribution is Normal. a.
Calculated from data. b.
NPar Tests
Group Statistics 69 5,377 2,6015 ,3132 0a . . . 69 156,16 19,500 2,348 68 119,41 9,601 1,164 69 91,01 10,866 1,308 68 77,72 5,425 ,658 69 39,29 4,141 ,499 68 57,57 11,949 1,449 69 7,299 ,8235 ,0991 68 5,210 1,1496 ,1394 69 ,868 ,2452 ,0295 68 ,734 ,1850 ,0224 69 80,676 19,6687 2,3678 68 99,090 21,4183 2,5974 Group Ht Non Ht Ht Non Ht Ht Non Ht Ht Non Ht Ht Non Ht Ht Non Ht Ht Non Ht Lama HT TDS TDD HDL AU Creatinin Cr Cl N Mean Std. Deviation Std. Error Meant cannot be computed becaus e at leas t one of the groups is empty. a.
Independent Samples Test
6,348 ,013 4,402 135 ,000 17,967 4,082 9,895 26,040 4,393 124,028 ,000 17,967 4,090 9,871 26,063 ,648 ,422 5,675 135 ,000 13,743 2,422 8,953 18,532 5,682 131,183 ,000 13,743 2,418 8,958 18,527 9,917 ,002 3,936 135 ,000 16,640 4,227 8,280 25,000 3,928 124,389 ,000 16,640 4,236 8,256 25,024 12,727 ,000 8,835 135 ,000 11,452 1,296 8,888 14,015 8,860 119,394 ,000 11,452 1,293 8,892 14,011 1,465 ,228 7,366 135 ,000 ,2561 ,0348 ,1874 ,3249 7,373 133,068 ,000 ,2561 ,0347 ,1874 ,3248 4,350 ,039 6,992 135 ,000 4,112 ,588 2,949 5,275 7,001 131,418 ,000 4,112 ,587 2,950 5,273 Equal variances as sumed Equal variances not ass umed Equal variances as sumed Equal variances not ass umed Equal variances as sumed Equal variances not ass umed Equal variances as sumed Equal variances not ass umed Equal variances as sumed Equal variances not ass umed Equal variances as sumed Equal variances not ass umed TG LDL T CHOL Ureum Creatinin BUN F Sig.
Levene's Test for Equality of Variances
t df Sig. (2-tailed) Mean Difference
Std. Error
Difference Lower Upper 95% Confidence
Interval of the Difference t-test for Equality of Means
Mann-Whitney Test
NPar Tests
Mann-Whitney Test
Ra nks 69 100,73 6950,50 68 36,80 2502,50 137 69 93,24 6433,50 68 44,40 3019,50 137 Group Ht Non Ht Total Ht Non Ht Total TDS TDDN Mean Rank Sum of Ranks
Test Statisticsa 156,500 673,500 2502,500 3019,500 -9,523 -7,616 ,000 ,000 Mann-Whitney U Wilcoxon W Z
As ymp. Sig. (2-tailed)
TDS TDD
Grouping Variable: Group a. Ranks 69 89,49 6174,50 68 48,21 3278,50 137 Group Ht Non Ht Total BUN
N Mean Rank Sum of Ranks
Test Statisticsa 932,500 3278,500 -6,110 ,000 Mann-Whitney U Wilcoxon W Z
As ymp. Sig. (2-tailed)
BUN
Grouping Variable: Group a.
Group Statistics 69 5,377 2,6015 ,3132 0a . . . 69 156,16 19,500 2,348 68 119,41 9,601 1,164 69 91,01 10,866 1,308 68 77,72 5,425 ,658 69 39,29 4,141 ,499 68 57,57 11,949 1,449 69 7,299 ,8235 ,0991 68 5,210 1,1496 ,1394 69 ,868 ,2452 ,0295 68 ,734 ,1850 ,0224 69 80,676 19,6687 2,3678 68 99,090 21,4183 2,5974 Group Ht Non Ht Ht Non Ht Ht Non Ht Ht Non Ht Ht Non Ht Ht Non Ht Ht Non Ht Lama HT TDS TDD HDL AU Creatinin Cr Cl N Mean Std. Deviation Std. Error Mean
t cannot be computed becaus e at leas t one of the groups is empty. a.
Independent Samples Test
38,907 ,000 13,961 135 ,000 36,748 2,632 31,542 41,953 14,024 99,462 ,000 36,748 2,620 31,548 41,947 14,992 ,000 9,039 135 ,000 13,294 1,471 10,385 16,203 9,079 100,237 ,000 13,294 1,464 10,389 16,199 49,490 ,000 -12,000 135 ,000 -18,284 1,524 -21,297 -15,270 -11,931 82,659 ,000 -18,284 1,532 -21,332 -15,236 10,528 ,001 12,237 135 ,000 2,0883 ,1707 1,7508 2,4258 12,208 121,325 ,000 2,0883 ,1711 1,7496 2,4269 5,262 ,023 3,615 135 ,000 ,1343 ,0372 ,0608 ,2078 3,622 126,410 ,000 ,1343 ,0371 ,0609 ,2077 ,641 ,425 -5,243 135 ,000 -18,4145 3,5125 -25,3611 -11,4679 -5,239 133,672 ,000 -18,4145 3,5147 -25,3660 -11,4630 Equal variances as sumed Equal variances not ass umed Equal variances as sumed Equal variances not ass umed Equal variances as sumed Equal variances not ass umed Equal variances as sumed Equal variances not ass umed Equal variances as sumed Equal variances not ass umed Equal variances as sumed Equal variances not ass umed TDS TDD HDL AU Creatinin Cr Cl F Sig.
Levene's Test for Equality of Variances
t df Sig. (2-tailed)
Mean Difference
Std. Error
Difference Lower Upper
95% Confidence Interval of the
Difference t-test for Equality of Means
Group Statistics 69 100,97 18,823 2,266 68 102,91 18,688 2,266 69 58,77 7,205 ,867 68 58,82 6,990 ,848 69 165,70 7,423 ,894 68 165,29 7,709 ,935 69 21,302 1,0405 ,1253 68 21,442 1,0783 ,1308 Group Ht Non Ht Ht Non Ht Ht Non Ht Ht Non Ht KGD Berat badan Tinggi badan IMT N Mean Std. Deviation Std. Error Mean
T-Test (pria)
Independent Samples Test
,001 ,970 -,606 135 ,546 -1,941 3,205 -8,279 4,398 -,606 134,992 ,546 -1,941 3,205 -8,279 4,397 ,002 ,965 -,046 135 ,964 -,055 1,213 -2,455 2,344 -,046 134,967 ,964 -,055 1,213 -2,454 2,343 ,426 ,515 ,311 135 ,757 ,402 1,293 -2,155 2,959 ,310 134,628 ,757 ,402 1,293 -2,156 2,959 ,001 ,973 -,772 135 ,442 -,1397 ,1810 -,4978 ,2183 -,772 134,659 ,442 -,1397 ,1811 -,4979 ,2184 Equal variances assumed Equal variances not assumed Equal variances assumed Equal variances not assumed Equal variances assumed Equal variances not assumed Equal variances assumed Equal variances not assumed KGD Berat badan Tinggi badan IMT F Sig.
Levene's Test for Equality of Variances
t df Sig. (2-tailed)
Mean Difference
Std. Error
Difference Lower Upper 95% Confidence
Interval of the Difference t-test for Equality of Means
Group Statistics 36 7,708 ,7369 ,1228 35 5,786 ,9438 ,1595 Group Ht Non Ht AU N Mean Std. Deviation Std. Error Mean
Independent Samples Test
4,388 ,040 9,583 69 ,000 1,9226 ,2006 1,5224 2,3229
9,550 64,306 ,000 1,9226 ,2013 1,5205 2,3248
Equal variances as sumed Equal variances not ass umed AU
F Sig.
Levene's Test for Equality of Variances
t df Sig. (2-tailed)
Mean Difference
Std. Error
Difference Lower Upper
95% Confidence Interval of the
Difference t-test for Equality of Means
T-Test (wanita)
Tabel Chi -square hubunganhipertensiessensialdenganhiperurisemia Group Statistics 33 6,852 ,6723 ,1170 33 4,600 1,0365 ,1804 Group Ht Non Ht AU N Mean Std. Deviation Std. Error Mean
Independent Samples Test
4,674 ,034 10,469 64 ,000 2,2515 ,2151 1,8219 2,6812
10,469 54,875 ,000 2,2515 ,2151 1,8205 2,6825
Equal variances as sumed Equal variances not ass umed AU
F Sig.
Levene's Test for Equality of Variances
t df Sig. (2-tailed)
Mean Difference
Std. Error
Difference Lower Upper
95% Confidence Interval of the
Difference t-test for Equality of Means
Crosstab 28 62 90 45,3 44,7 90,0 31,1% 68,9% 100,0% 40,6% 91,2% 65,7% 20,4% 45,3% 65,7% 41 6 47 23,7 23,3 47,0 87,2% 12,8% 100,0% 59,4% 8,8% 34,3% 29,9% 4,4% 34,3% 69 68 137 69,0 68,0 137,0 50,4% 49,6% 100,0% 100,0% 100,0% 100,0% 50,4% 49,6% 100,0% Count Expected Count % within AU % within Group % of Total Count Expected Count % within AU % within Group % of Total Count Expected Count % within AU % within Group % of Total Normo Uricemia Hyperuricemia AU Total Ht Non Ht Group Total Chi-Square Tests 38,903b 1 ,000 36,690 1 ,000 42,418 1 ,000 ,000 ,000 38,619 1 ,000 137 Pearson Chi-Square Continuity Correctiona Likelihood Ratio Fis her's Exact Test Linear-by-Linear As sociation N of Valid Cases Value df As ymp. Sig. (2-sided) Exact Sig. (2-sided) Exact Sig. (1-sided)
Computed only for a 2x2 table a.
0 cells (,0%) have expected count less than 5. The minimum expected count is 23,33. b. Risk Estimate ,066 ,025 ,174 ,357 ,257 ,494 5,396 2,523 11,540 137 Odds Ratio for AU
(Normo Uricemi a / Hyperuricem ia) For cohort Group = Ht For cohort Group = Non Ht
N of Valid Cases
Value Lower Upper
95% Confidence Interval
T-Test pria
Reratakadar AUs berdasarkan lama menderita HT (Pria)
T-Test wanita
Reratakadar AUs berdasarkan lama menderita HT (wanita) Group Sta tisti cs
21 39,43 3,544 ,773 15 36,40 2,995 ,773 21 7,557 ,6454 ,1408 15 7,920 ,8248 ,2130 Lama HT < 5 tahun >= 5 tahun < 5 tahun >= 5 tahun HDL AU
N Mean St d. Deviat ion
St d. E rror Mean
Independent Samples Test
,734 ,398 2,691 34 ,011 3,029 1,125 ,742 5,316 2,769 32,940 ,009 3,029 1,094 ,803 5,254 ,490 ,489 -1,481 34 ,148 -,3629 ,2450 -,8607 ,1350 -1,421 25,509 ,167 -,3629 ,2553 -,8882 ,1625 Equal variances as sumed Equal variances not ass umed Equal variances as sumed Equal variances not ass umed HDL
AU
F Sig.
Levene's Test for Equality of Variances
t df Sig. (2-tailed) Mean Difference
Std. Error
Difference Lower Upper 95% Confidence
Interval of the Difference t-test for Equality of Means
Independent Samples Test
1,887 ,179 3,599 31 ,001 4,869 1,353 2,110 7,628 4,070 30,633 ,000 4,869 1,196 2,428 7,310 ,019 ,892 -1,528 31 ,137 -,3643 ,2384 -,8504 ,1218 -1,514 22,394 ,144 -,3643 ,2406 -,8627 ,1341 Equal variances as sumed Equal variances not ass umed Equal variances as sumed Equal variances not ass umed HDL
AU
F Sig.
Levene's Test for Equality of Variances
t df Sig. (2-tailed)
Mean Difference
Std. Error
Difference Lower Upper
95% Confidence Interval of the
Difference t-test for Equality of Means
Proporsihiperurisemiaberdasarkan Lama HT Group Sta tisti cs
21 42,29 4,221 ,921 12 37,42 2,644 ,763 21 6,719 ,6509 ,1420 12 7,083 ,6726 ,1942 Lama HT < 5 tahun >= 5 tahun < 5 tahun >= 5 tahun
